Cosimi Reese A, Beik Nahal, Kubiak David W, Johnson Jennifer A
Department of Pharmacy, Massachusetts General Hospital.
Center for Drug Policy, Partners Healthcare.
Open Forum Infect Dis. 2017 May 2;4(2):ofx084. doi: 10.1093/ofid/ofx084. eCollection 2017 Spring.
Ceftaroline is approved by the Food and Drug Administration for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia, including cases with concurrent bacteremia. Use for serious methicillin-resistant (MRSA) infections has risen for a multitude of reasons. The aim of this article is to review the literature evaluating clinical outcomes and safety of ceftaroline prescribed for serious MRSA infections. We conducted a literature search in Ovid (Medline) and PubMed for reputable case reports, clinical trials, and reviews focusing on the use of ceftaroline for treatment of MRSA infections. Twenty-two manuscripts published between 2010 and 2016 met inclusion criteria. Mean clinical cure was 74% across 379 patients treated with ceftaroline for severe MRSA infections. Toxicities were infrequent. Ceftaroline treatment resulted in clinical and microbiologic cure for severe MRSA infections. Close monitoring of hematological parameters is necessary with prolonged courses of ceftaroline.
头孢洛林已获美国食品药品监督管理局批准用于治疗急性细菌性皮肤及皮肤结构感染和社区获得性细菌性肺炎，包括并发菌血症的病例。由于多种原因，其用于治疗严重耐甲氧西林金黄色葡萄球菌（MRSA）感染的情况有所增加。本文旨在综述评估头孢洛林用于治疗严重MRSA感染的临床疗效和安全性的文献。我们在Ovid（医学文献数据库）和PubMed上进行了文献检索，查找关于头孢洛林用于治疗MRSA感染的知名病例报告、临床试验及综述。2010年至2016年间发表的22篇手稿符合纳入标准。在379例接受头孢洛林治疗严重MRSA感染的患者中，平均临床治愈率为74%。不良反应较少见。头孢洛林治疗可使严重MRSA感染实现临床和微生物学治愈。长期使用头孢洛林时，有必要密切监测血液学参数。
